Superluminal Medicines Raises $60 Million for Obesity Drug Trial

Sep 3, 2026
The Series B financing will support a Phase 1 trial of a treatment for rare genetic forms of obesity by the end of 2026.

Superluminal Medicines has closed an oversubscribed $60 million Series B financing, the company announced in a press release. The round was led by BVF Partners, with participation from Deep Track Capital, Perceptive Advisors and existing investors including RA Capital Management, Insight Partners, NVIDIA and Eli Lilly and Company.

The funding will support a Phase 1 clinical trial by the end of 2026 for Superluminal's lead program, a selective MC4R agonist for rare genetic forms of obesity and hypothalamic obesity. The company said the drug selectively activates signaling pathways associated with therapeutic effects while limiting side effects.

Superluminal will also use the capital to advance other programs and expand its GPCR discovery platform for endocrine and cardiometabolic diseases. The platform combines structural biology, cryo electron microscopy, small molecule design, predictive toxicity models, machine learning and GPCR biophysics.

We hope you enjoyed this article

Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Whitepaper

Tensordyne Napier: What If One Rack Could Do the Work of Nine?

Tensordyne

This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.

Read more

You may also like

Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.